Geetha Shankar

Head of Clinical Development Oncology at Amunix

Dr. Geetha Shankar serves as the Senior Vice President of Clinical Science and Clinical Operations at Amunix. She has over 25 years of experience in drug discovery and development, with expertise extending from high throughput screening and drug discovery, to clinical development (IND to phase III), regulatory filings, and market access. Before joining Amunix, Dr. Shankar spent 10 years at Genentech as Group Clinical Science Director. In this capacity she oversaw US, EU, and global approvals of Tecentriq® in non-small cell lung cancer. She was also a key contributor on the PI3K program and worked in both breast and lung cancer indications on proof-of-concept studies. Prior to Genentech, she worked at Exelixis for six years, first as a team leader on drug discovery projects, and later transitioning to clinical development. In the latter function, she worked on early trials for cabozantinib in medullary thyroid cancer. Prior to Exelixis, she worked at Ceretek LLC, an oncology startup focused on lipid G-protein coupled receptors.

Dr. Shankar received a Ph.D. in Molecular Pharmacology from Northwestern University School of Medicine and an M.S. in Medicinal Chemistry from the University of the Sciences in Philadelphia. She also holds a B.Pharm. from the College of Pharmacy in Bangalore, India.